Are we really active in the prevention of obesity and type 2 diabetes at the community level?

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 5, 2011, Pages 380-389

  Uusitupa, M ^a   Tuomilehto, J ^b   Puska, P ^c  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Health policy; Intervention; Lifestyles; Population based strategy; Prevention; Primary health care; Type 2 diabetes

Indexed keywords

COMMUNITY CARE; EPIDEMIC; FINLAND; HEALTH PROMOTION; HUMAN; LIFESTYLE; MOTOR ACTIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SHORT SURVEY;

COMMUNITY HEALTH SERVICES; DIABETES MELLITUS, TYPE 2; EPIDEMICS; FINLAND; HEALTH PROMOTION; HUMANS; LIFE STYLE; MOTOR ACTIVITY; OBESITY; PREVALENCE; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 79954633330     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.12.007     Document Type: Short Survey

References (73)

1. WHO Technical report series 844 Prevention of diabetes Mellitus, report of a WHO Study Group 1994, World Health Organization.
2. IDF Diabetes Atlas. http://www.diabetesatlas.org.
3. Chan J., Malik V., Jia W., Kadowaki T., Yajnik C., Yoon K.-H., et al. Diabetes in Asia. Epidemiology, risk factors, and pathophysiology. JAMA 2009, 301:2129-2140.
4. Yang W., Lu J., Weng J., Jia W., Ji L., Xiao J., et al. Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362:1090-1101. for the China National Diabetes and Metabolic Disorders Study Group.
5. Misra A., Khurana L. Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008, 93:S9-S30.
6. James W.P.T. The epidemiology of obesity: the size of the problem. J Intern Med 2008, 263:336-352.
7. Pan X.R., Li G.W., Hu Y.H., Wang J.X., Yang W.Y., An Z.X., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care 1997, 20:537-544.
8. Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hämäläinen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.
9. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. Diabetes Prevention Program Research Group.
10. Kosaka K., Noda M., Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005, 67:152-162.
11. Ramachandran A., Snehalatha C., Mary S., Mukesh B., Bhaskar A.D., Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance [IDPP-1]. Diabetologia 2006, 49:289-297. Indian Diabetes Prevention Programme [IDDP].
12. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003, 26:977-980. The Diabetes Prevention Program Research Group.
13. Lindström J., Ilanne-Parikka P., Peltonen M., Aunola S., Eriksson J.G., Hemiö K., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish diabetes prevention study. Lancet 2006, 368:1673-1679. On behalf of the Finnish Diabetes Prevention Study Group.
14. Li G., Zhang P., Wang J., Gregg E.W., Yang W., Gong Q., et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing diabetes prevention study: a 20-year follow-up study. Lancet 2008, 371:1783-1789.
15. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcome study. Lancet 2009, 374:1677-1686. Diabetes Prevention Program Research Group.
16. Gillies C, Abrams K, Lambert P, Cooper N, Sutton A, Hsu R, Khunti K. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ doi:10.1136/bmj.39063.689375.55.
17. Naser K., Gruber A., Thomson G. The emerging pandemic of obesity:are we doing enough the prevent a disaster?. Int J Clin Pract 2006, 60:1093-1097.
18. Egger G. Health, " illth", and economic growth. Medicine, environment, and economics at the crossroad. Am J Prev Med 2009, 37:78-83.
19. Ryan J.G. Cost and policy implications from the increasing prevalence of obesity and diabetes mellitus. Gend Med 2009, 6(Suppl. 1):86-108.
20. Jia H., Lubetkin E.I. Obesity-related quality-adjusted life years lost in the U.S. from 1993 to 2008. Am J Prev Med 2010, 39:220-227.
21. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia, report of a WHO/IDF consultation 2006, World Health Organisation.
22. Glucose tolerance and cardiovascular mortality. Arch Intern Med 2001, 161:397-404. The DECODE Study Group, on behalf of the European Diabetes Epidemiology Group.
23. Ning F., Tuomilehto J., Pyörälä K., Onat A., Söderberg S., Qiao Q. Cardiovascular disease mortality in Europeans in relation to fasting and 2h plasma glucose levels within a normoglycemic range. Diabetes Care 2010 Apr 27, for the DECODE Study Group.
24. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 2009, 373:1083-1096. Prospective Studies collaboration.
25. Saaristo T., Moilanen L., Jokelainen J., Korpi-Hyövälti E., Vanhala M., Saltevo J., et al. Cardiometabolic profile of people screened for high risk of type 2 diabetes in a national diabetes prevention programme [FIN-D2D]. Prim Care Diabetes 2010, 10.1016/j.pcd.2010.05.005.
26. Vimaleswaran K.S., Loos R.J. Progress in the genetics of common obesity and type 2 diabetes. Expert Rev Mol Med 2010 Feb 26, 12:e7.
27. McCarthy M.I., Zeggini E. Genome-wide association studies in type 2 diabetes. Curr Diab Rep 2009, 9(2):164-171.
28. Eriksson J.G. Early programming of later health and disease: factors acting during prenatal life might have lifelong consequences. Diabetes 2010, 59:2349-2350.
29. Kolb H., Mandrup-Poulsen T. The global diabetes epidemic as a consequence of life-style induced low-grade inflammation. Diabetologia 2010, 53:10-20.
30. Herder C., Peltonen M., Koenig W., Sutfels K., Lindström J., Martin S., et al. Anti-inflammatory effect of lifestyle changes in the Finnish diabetes prevention study. Diabetologia 2009, 52:433-442.
31. Lindström J., Louheranta A., Mannelin M., Rastas M., Salminen V., Eriksson J., et al. The Finnish diabetes prevention study. Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 2003, 26:3230-3236.
32. Roumen C., Blaak E., Corpeleijn E. Lifestyle intervention for prevention of diabetes: determinants of success for future implementation. Nutr Rev 2009, 67:132-146.
33. Horton E. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large efficacy trials. Obesity 2009, 17(Suppl. 3):S43-S48.
34. Simmons R, Unwin N, Griffin S. International diabetes federation: an update of the evidence concerning the prevention of type 2 diabetes. Diab Res Clin Pract. doi:10.1016/j.diabres.2009.10.003.
35. Baker M., Simpson K., Lloyd B., Bauman A., Fiatorone Singh M.A. Behavioral strategies in diabetes prevention programs: a systematic review of randomized controlled trials. Diab Res Clin Pract 2010, 10.1016/j.diabres.2010.06.030.
36. Yates T., Khunti K., Bull F., Gorely T., Davies M. The role of physical activity in the management of impaired glucose tolerance: a systematic review. Diabetologia 2007, 50:1116-1126.
37. Uusitupa M., Peltonen M., Lindström J., Aunola S., Ilanne-Parikka P., Keinänen-Kiukaanniemi S., et al. Ten-year mortality and cardiovascular morbidity in the Finnish diabetes prevention study - secondary analysis of the randomized trial. PLoS One 2009 May 21, 4(5):e5656. Finnish Diabetes Prevention Study Group.
38. Eriksson K.F., Lindgärde F. No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmö preventive trial with diet and exercise. Diabetologia 1998, 41:1010-1016.
39. Gillies C, Lambert P, Abrams K, Sutton A, Cooper N, Hsu R, et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ doi:10.1136/bmj.39545.58289.25.
40. Lindgren P., Lindström J., Tuomilehto J., Uusitupa M., Peltonen M., Jönsson B., et al. Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective. Int J Technol Health Care 2007, 23:177-183. DPS Study Group.
41. Schaufler T.M., Wolff M. Cost effectiveness of preventive screening programmes for type 2 diabetes in Germany. Appl Health Econ Policy 2010, 8:191-202.
42. Kahn R., Alperin P., Eddy D., Borch-Johnsen K., Feigelman J., Gregg E., et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 2010, 375:1365-1374.
43. Li R., Zhang P., Barker L.E., Chowdhury F.M., Xhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care 2010, 33:1872-1894.
44. Puska P. From Framingham to North Karelia From descriptive epidemiology to public health action. Prog Cardiovasc Dis 2010, 53:15-20.
45. Vartiainen E., Puska P., Pekkanen J., Tuomilehto J., Jousilahti P. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland. BMJ 1994, 309:23-27.
46. Vartiainen E., Sarti C., Tuomilehto J., Kuulasmaa K. Do changes in cardiovascular risk factors explain changes in mortality from stroke in Finland?. BMJ 1995, 310:901-904.
47. Implementation of type 2 diabetes prevention plan. Project plan 2003-2007, FIN-D2D project 2006, Finnish Diabetes Association, Tampere. http://www.diabetes.fi/tiedoston_katsominen.php%3Fdok_id%3D458.
48. Saaristo T., Peltonen M., Keinänen-Kiukaanniemi S., Vanhala M., Saltevo J., Niskanen L., et al. National Type 2 diabetes prevention programme in Finland: FIN-D2D. Int J Circumpolar Health 2007, 66:101-112.
49. Saaristo T., Moilanen L., Korpi-Hyövälti E., Vanhala M., Saltevo J., Niskanen L., et al. Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish national diabetes prevention program (FIN-D2D). Diabetes Care 2010, 33:2146-2151.
50. Laatikainen T., Dunbar J.A., Chapman A., Kilkkinen A., Vartiainen E., Heistaro S., et al. Prevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting. Greater Green Triangle (GTT) Diabetes prevention Project. BMC Public Health 2007 Sep 19, 7:249.
51. Philpot B., Absetz P., Bunker S., O'Neil A., Reddy P., Best J.D., et al. Prevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting. Greater Green Triangle (GTT) Diabetes Prevention Project. BMC Public Health 2007 Sep 19, 7:249.
52. Absetz P., Oldenburg B., Hankonen N., Valve R., Heinonen H., Nissinen A., et al. Type 2 diabetes prevention in the real life. Three-year results of the GOAL lifestyle implementation trial. Diabetes Care 2009, 32:1418-1420.
53. Seidel M., Powell R., Zgibor J., Siminerio L., Piatt G. Translating the diabetes prevention program into an urban medically inderserved community. A nonrandomized prospective intervention study. Diabetes Care 2008, 31:684-689.
54. Ackermann R., Finch E., Brizendine E., Zhou H., Marrero D. Translating the diabetes prevention program into the community. The DEPLOY pilot study. Am J Prev Med 2008, 35:357-363.
55. Kulzer B., Hermanns N., Gorges D., Schwarz P., Haak T. Prevention of diabetes self-management program [PREDIAS]: effects on weight, metabolic risk factors, and behavioral outcomes. Diabetes Care 2009, 32:1143-1146.
56. Eriksson M, Franks P, Eliasson M. A-3-year randomized trial of lifestyle intervention for cardiovascular risk reduction in the primary care setting: the Swedish Björknäs study. PloS One 4(4):e5195. doi:10.1371/journal.pone.0005195.
57. Makrikalis K., Liatis S., Grammatikou S., Perrea D., Katsilambros N. Original article: implementation and effectiveness of the first community lifestyle intervention programme to prevent type 2 diabetes in Greece. The DE-PLAN study. Diabet Med 2010, 27:459-465.
58. Parikh P., Simon E., Kezhen F., Looker H., Goytia C., Horowitz C. Results of a pilot diabetes prevention intervention in East Harlem, New York City: project HEED. Am J Pub Health 2010, 100(S1):S232-S239.
59. Lindström J., Tuomilehto J. The Diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003, 26:725-731.
60. Bjärås G., Ahlbom A., Alvarsson M., Burström B., Diderichsen F., Efendic S., et al. Strategies and methods for implementing a community-based diabetes primary prevention program in Sweden. Health Promot Int 1997, 1(§2):151-160.
61. Andersson C.M., Bjärås G., Tillgren P., Östenson C.-G. A longitudinal assessment of inter-sectional participation in a community-based diabetes prevention programme. Soc Sci Med 2005, 61:2407-2422.
62. Yates T., Davies M., Gorely T., Bull F., Khunti K. Rationale, design and the baseline data from prediabetes risk education and physical activity recommendation and encouragement [PREPARE] programme study: a randomized controlled trial. Patient Educ Couns 2008, 73:264-271.
63. Amundson H., Butcher M., Gohdes D., Hall T., Harwell T., Helgerson S., et al. Translating the diabetes prevention program into practice in the general community. The Diabetes Educator 2009, 35:209-222.
64. Davidson M.R. Establishing prevention, education and community awareness through a comprehensive diabetes, hypertension and hypercholesteroaemia screening programme. The Smith Island, Maryland, USA experience. Int J Nurs Pract 2004, 10:242-246.
65. Genz J., Haastert B., Meyer G., Steckelberg A., Muller H., Verheyem F., et al. Blood glucose testing and primary prevention of diabetes mellitus type 2 - evaluation of the effect of evidence based patient information. BMC Public Health 2010, 10:15.
66. Katula J.A., Vitolins M.Z., Rosenberger E.L., Blackwell C., Espeland M.A., Lawlor M.S., et al. Healthy living partnerships to prevent diabetes [HELP PD]: design and methods. Contemp Clin Trials 2010, 31:71-81.
67. Webb D.R., Khunti K., Srinivasan B., Gray L.J., Taub N., Campbell S., et al. Rationale and design of the addition-leicerter study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular intervention in people with type 2 diabetes mellitus detected by screening. BMC Trial 2010, 11:16.
68. Colagiuri S., Vita P., Cardona-Morrell M., Singh M., Farrell L., Milat A., et al. The Sydney diabetes prevention program: a community-based translational study. BMC Public Health 2010, 10:328.
69. Uusitupa M. Early lifestyle intervention in patients with non-insulin dependent diabetes mellituys and impaired glucose tolerance. Ann Med 1996, 28:445-449.
70. Paulweber B., Valensi P., Lindström J., Lalic N.M., Greaves C.J., McKee M., et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res 2010 Apr, 42(Suppl. 1):S3-S36.
71. Lindström J., Neumann A., Sheppard K.E., Gilis-Januszewska A., Greaves C.J., Handke U., et al. Take action to prevent diabetes - the IMAGE toolkit for the prevention of type 2 diabetes in Europe. Horm Metab Res 2010 Apr, 42(Suppl. 1):S37-S55.
72. Pajunen P., Landgraf R., Muylle F., Neumann A., Lindström J., Schwarz P.E., et al. Quality indicators for the prevention of type 2 diabetes in Europe - IMAGE. Horm Metab Res 2010 Apr, 42(Suppl. 1):S56-S63.
73. Saaristo T., Peltonen M., Lindström J., Saarikoski L., Sundvall J., Eriksson J., et al. Cross-sectional evaluation of the Finnish diabetes risk score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res 2005, 2:67-72.